Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Supernus Pharmaceuticals

Supernus Pharmaceuticals reported $731.54M in Current Liabilities for its fiscal quarter ending in March of 2023.

Current Liabilities Change
Abbott ABT:US USD 14.53B 959M
ANI Pharmaceuticals ANIP:US USD 125.82M 26.39M
Cara Therapeutics CARA:US USD 16.68M 6.78M
Corcept Therapeutics CORT:US USD 78.86M 6.37M
Eisai 4523:JP JPY 298.94B 14.73B
Eli Lilly LLY:US USD 16.01B 1.13B
Endo International ENDP:US USD 606.64M 82.98M
Horizon Pharma HZNP:US USD 884.89M 64.25M
Marinus Pharmaceuticals MRNS:US USD 21.51M 3.5M
Pacira PCRX:US USD 98.7M 49.08M
Perrigo PRGO:US USD 1.09B 26.8M
Revance Therapeutics RVNC:US USD 77.98M 2.3M
Supernus Pharmaceuticals SUPN:US USD 731.54M 43.59M
United Therapeutics UTHR:US USD 324.6M 18.6M
Xeris Pharmaceuticals Inc XERS:US USD 81.42M 7.8M